Moderna and Samsung Biologics announced a Manufacturing Services and Supply Agreement in which Samsung Biologics will provide large scale, commercial fill-finish manufacturing for mRNA-1273, Moderna's COVID-19 vaccine. Upon execution of the deal, technology transfer will commence immediately at Samsung Biologics' facilities in Incheon, South Korea, utilizing a production line equipped for aseptic fill-finish, labeling, and packaging services to support the production of hundreds of millions of doses of Moderna's COVID-19 vaccine intended for the supply of markets outside of the U.S. starting in the third quarter of 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
117.3 USD | -4.39% | -6.15% | +17.96% |
May. 10 | Equities Mostly Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey | MT |
May. 10 | S&P 500, Dow Rise as Traders Parse Fed Officials' Comments, Consumer Sentiment Survey | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B | |
+20.18% | 11.72B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine